| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PLB; CMD1P; CMH18 |
| WB Predicted band size | 6 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human PLN |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条与PLN(Phospholamban)抗体相关的参考文献及其简要摘要：
---
1. **文献名称**：*Autoantibodies Against Cardiac β1-Adrenoceptor and Phospholamban in Patients with Chronic Heart Failure*
**作者**：Jahns R, et al.
**摘要**：该研究发现，慢性心力衰竭患者体内存在针对β1-肾上腺素受体和磷蛋白(PLN)的自身抗体，可能通过干扰心肌细胞钙离子调控通路加重心脏功能障碍。
---
2. **文献名称**：*Phospholamban Antibodies Detect Functional Protein Defects in Genetic Cardiomyopathy*
**作者**：Schmitt JP, et al.
**摘要**：研究利用PLN特异性抗体检测遗传性扩张型心肌病患者的组织样本，发现PLN表达水平及磷酸化状态异常，提示其在钙循环失调中的病理作用。
---
3. **文献名称**：*Role of Anti-Phospholamban Autoantibodies in Cardiac Arrhythmias*
**作者**：Caforio ALP, et al.
**摘要**：探讨PLN自身抗体与心律失常的关联，发现抗体可能通过结合PLN并抑制其与SERCA2a的相互作用，导致心肌细胞钙超载和电活动异常。
---
4. **文献名称**：*Immunohistochemical Analysis of Phospholamban in Human Myocardium Using Monoclonal Antibodies*
**作者**：Fujii J, et al.
**摘要**：开发并验证了针对PLN的单克隆抗体，用于心肌组织免疫组化分析，为研究PLN在正常和病变心脏中的分布及调控机制提供工具。
---
以上文献涵盖PLN抗体的病理机制、诊断应用及实验工具开发，可根据研究需求进一步查阅原文。
**Background of PLN Antibodies**
Phospholamban (PLN) is a critical regulatory protein in cardiac and skeletal muscle, primarily modulating calcium cycling in the sarcoplasmic reticulum (SR). It acts as an inhibitor of the SR calcium ATPase (SERCA2a), a pump responsible for resequestering calcium during muscle relaxation. When unphosphorylated, PLN binds to SERCA2a, reducing its activity and delaying calcium uptake. Upon phosphorylation (e.g., via β-adrenergic signaling), PLN dissociates, enhancing SERCA2a function and promoting faster calcium reuptake, thereby improving myocardial relaxation and contractility.
PLN dysfunction is linked to cardiomyopathies, heart failure, and arrhythmias. Mutations in the *PLN* gene, such as the R14del variant, are associated with inherited dilated cardiomyopathy and arrhythmogenic disorders. Antibodies targeting PLN are vital tools in research and diagnostics. They enable the detection of PLN expression levels, phosphorylation status (e.g., at Ser16 or Thr17), and localization in tissues via techniques like Western blot, immunohistochemistry, or immunofluorescence. These antibodies help elucidate PLN's role in disease mechanisms, evaluate therapeutic interventions (e.g., gene therapy targeting SERCA2a/PLN), and validate experimental models. Commercial PLN antibodies are typically validated for specificity across species, including human, mouse, and rat, supporting translational research in cardiovascular biology.
×
